Direct has way too much closed system automated and reduced cost value to be sold this early for anything close to an honest net present worth that a big pharma would pay for because of how far along in development it has come before the next trial. Linda knows this and so do many large holders of this stock. No way this gets bought cheap but a partnership that recognizes this value without having to pay for all of it up front could work under the right development terms. Best wishes.
Market Data 
Markets 
AI
